The development of NAFLD is tightly tied to other clinical developments such as obesity, dyslipidemia, diabetes, and metabolic syndrome [65], associated with NAFLD extensively, such as PPAR, AMPK, PI3K-Akt, ER stress, TNF-α, and FAAs, and also associated with NAFLD progression. Here, AKT1 is linked to metabolic dysfunction-associated steatotic liver disease.